Cancer AI Startup Triomics raises $22M amid growing oncology workloads
Synopsis
Triomics has secured $22 million in Series B funding to expand its oncology AI platform used by cancer centers. The investment comes as global cancer cases continue to rise, increasing demand for tools that help healthcare providers manage patient records, clinical trials, and reporting requirements.
Triomics raised $22 million to expand its oncology AI platform as cancer centers manage growing patient data volumes and increasing global cancer cases, according to international health estimates.
Key Highlights
- Triomics raised $22 million in a Series B funding round.
- Total disclosed funding has reached at least $37 million since 2024.
- IARC projects annual global cancer cases could reach 35 million by 2050.
- Company provides oncology AI tools for clinical trials and reporting workflows.
- Enterprise customer base increased fourfold over the past year, according to Triomics.
Triomics has raised $22 million in a Series B funding round as healthcare providers face growing challenges managing cancer patient data, clinical trials, and reporting requirements.
The startup, established in 2021, creates oncology AI software that cancer facilities use to handle intricate medical records and aid clinical processes. Battery Ventures led the round, which also featured participation from existing investors Nexus Venture Partners, Lightspeed and Y Combinator.
The investment is the company's latest raise after the $15 million Series A investment in 2024.
Cancer systems face growing data burden
The funding comes amid a steady increase in global cancer cases.
The International Agency for Research on Cancer (IARC) of the World Health Organisation estimated that there were 20 million new cancer cases globally in 2022 and 9.7 million cancer deaths.
The agency's updated estimates project that the number of cancer cases could rise by 77% to 35 million annually by 2050.
The healthcare industry is also handling more patient data, with personalised cancer care and higher cancer survival rates. Pathology reports, imaging data, treatment histories, physician notes and genomic data can all be found in records.
Focus on clinical trials and reporting
Triomics has started off by creating software that aids the identification of patients who may be eligible for clinical trials in cases of cancer. Since then, the company has developed its platform to incorporate tools and patient records summarization to facilitate administrative workflows.
The platform is also used for cancer registry reporting, a requirement for many healthcare organizations. Its technology is used by institutions such as Yale Cancer Center and Memorial Sloan Kettering Cancer Center, the company says.
Customer growth before expansion
Medical records are often thousands of pages long, which Sarim Khan, the co-founder, said is a challenge for oncology teams in terms of administrative workload.
Triomics said its enterprise customer base has quadrupled over the last year and ARR is now ten times higher. The company did not report revenues.
The money comes at a time when cancer centers and hospitals are increasingly testing specialized artificial intelligence (AI) applications that are designed to manage the proliferation of clinical information that accompanies cancer care.
FAQs
Q1. Why is Triomics' $22 million funding round attracting attention?
Triomics raised $22 million as cancer centers face growing volumes of patient data and increasing demand for oncology-focused AI tools.
Q2. What does Triomics' oncology AI platform do?
The platform helps healthcare teams review patient records, support clinical trial matching, and manage cancer registry reporting requirements.
Q3. How is India connected to Triomics?
Triomics was founded by Indian entrepreneurs and has emerged as one of the notable healthcare AI startups addressing cancer care challenges globally.
Follow Inspirepreneur Magazine for daily global business news
Pooja Malik is a business journalist with over six years of experience covering startups, entrepreneurship, and emerging trends. She has previously worked with leading media platforms such as YourStory Media and BW BusinessWorld, where she reported on business, policy, and market developments. Currently, she serves as Editor at The Inspirepreneur Magazine, where she writes and edits stories across business, lifestyle, and travel, with a focus on clarity, accuracy, and reader relevance.
